[1] Walsh TJ, Pappas P, Winston DJ, et al.Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever[J]. N Engl J Med, 2002, 346(4): 225-234. [2] Qian YY, Xu WY.Analysis of adverse reactions caused by yoriconazole in 36 cases[J]. Zhejiang Medical Education(浙江医学教育), 2018, 17(3): 61-63. [3] Zheng FY, Wu Y, Rao YF, et al.The role of Knott’s assessment scale in the evaluation of adverse drug reactions and case analysis[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2012, 47(8): 650-652. [4] Zonios DI, Gea-Banacloche J, Childs R, et al.Hallucinations during voriconazole therapy[J]. Clin Infect Dis, 2008, 47(1): e7-e10. [5] Xing Y, Chen L, Feng Y, et al.Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections[J]. BMC Infect Dis, 2017, 17(1): 798. [6] Qi YL.Severe psychotic symptoms and limb muscle tension caused by voriconazole in one patients[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2013, 10(10): 636-636, 638. [7] Wang Y, Cui XL, Liu LH.One case of mental abnormality induced by drug interaction[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(8): 499-500, 505. [8] Zou JL.Analysis of 31 adverse drug reaction/event cases induced by voriconazole[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2013, 10(10): 623-626. [9] Bayhan GI, Garipardic M, Karaman K, et al.Voriconazole-associated visual disturbances and hallucinations[J]. Cutan Ocul Toxicol, 2016, 35(1): 80-82. [10] Kinoshita J, Iwata N, Ohba M, et al.Mechanism of voriconazole-induced transient visual disturbance: reversible dysfunction of retinal ON-bipolar cells in monkeys[J]. Invest Ophthalmol Vis Sci, 2011, 52(8): 5058-5063. [11] Gautierveyret E, Fonrose X, Tonini J, et al.Variability of voricon-azole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels[J]. Antimicrob Agents Chemother, 2015, 59(4): 2305-2314. [12] Jin H, Wang T, Falcione BA, et al.Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis[J]. J Antimicrob Chemother, 2016, 71(7): 1772-1785. [13] Boyd AE, Modi S, Howard SJ, et al.Adverse reactions to voriconazole[J]. Clin Infect Dis, 2004, 39(8): 1241-1244. [14] Sakurada H, Yasuhara K, Kato K, et al.An investigation of visual hallucinations associated with voriconazole administration to patients with hematological malignancies[J]. Pharmazie, 2016, 71(11): 660-664. [15] Imhof A, Schaer DJ, Schanz U, et al.Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring[J]. Swiss Med Wkly, 2006, 136(45-46): 739-742. [16] Eiden C, Peyrière H, Cociglio M, et al.Adverse effects of voriconazole: analysis of the French pharmacovigilance database[J]. Ann Pharmacother, 2007, 41(5): 755-763. [17] Pasqualotto AC, Xavier Mo, Andreolla HF, et al.Voriconazole therapeutic drug monitoring: focus on safety[J]. Expert Opin Drug Saf, 2010, 9(1): 125-137. [18] Shao H, Yuan HZ, Jiang JJ. One case of seizure induced by voriconazole for injection[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(3): 62, 64. [19] Yang XN, Zhang XY, Wang YQ, et al.Discussion on the relationship between voriconazole drug adverse reactions and clinical intervention measures based on blood drug concentration[J]. The Journal of Nanjing Medical University(Natural Sciences) [南京医科大学学报(自然科学版)], 2018, 38(8):1144-1147. |